¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"B cell stimulating factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • fluorescence activated cell sorter
    Çü±¤Ç¥Áö¼¼Æ÷ºÐ·ù±â
  • foam cell
    °Åǰ¼¼Æ÷
  • follicle cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • follicular cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • foreign body giant cell
    À̹°°Å´ë¼¼Æ÷
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • G cell
    G¼¼Æ÷
  • Gaucher cell
    °í½¦¼¼Æ÷
  • germ cell
    Á¾ÀÚ¼¼Æ÷, »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • germinal cell
    Á¾ÀÚ¼¼Æ÷
  • ghost cell
    À¯·É¼¼Æ÷
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • giant cell
    °Å´ë¼¼Æ÷
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å´ë¼¼Æ÷Ä¡ÀºÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • ghost cell
    ¼¼Æ÷ÂßÀïÀÌ, À¯·É¼¼Æ÷
  • giant cell
    °Å´ë¼¼Æ÷
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • glandular cell
    »ù¼¼Æ÷
  • glial cell
    (¢¡neuroglial cell) ½Å°æ¾Æ±³¼¼Æ÷
  • glitter cell
    ¹Ý¦¼¼Æ÷
  • globoid cell
    °ø¼¼Æ÷, ±¸»ó¼¼Æ÷
  • glomus cell
    Å丮¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • gonadotrope cell
    (¢¡gonadotroph) »ý½Ä»ùÀڱؼ¼Æ÷
  • granule cell
    °ú¸³¼¼Æ÷
  • granulosa cell
    °ú¸³Ãþ¼¼Æ÷
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • hair cell
    Åм¼Æ÷
  • hairy cell
    Åиð¾ç¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • giant cell arteritis
    °Å¼¼Æ÷(¼º) µ¿¸Æ¿°
  • giant cell arteritis=temporal arteritis
    °Å¼¼Æ÷µ¿¸Æ¿°
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å¼¼Æ÷Ä¡ÀºÁ¾.
  • giant cell fibroblastoma
    °Å´ë¼¼Æ÷ ¼¶À¯¸ð¼¼Æ÷Á¾
  • giant cell glioma
    °Å¼¼Æ÷±³Á¾.
  • giant cell granuloma
    °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell granuloma,reparative
    ¼öº¹¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell histiocytoma
    °Å´ë¼¼Æ÷ Á¶Á÷±¸Á¾
  • giant cell leukemia
    °Å¼¼Æ÷¹éÇ÷º´.
  • giant cell myeloma
    °Å¼¼Æ÷°ñ¼öÁ¾.
  • giant cell myocarditis
    °Å´ë¼¼Æ÷¼º ½É±Ù¿°(¡­ãýÐÉæú)
  • giant cell pneumonia
    °Å¼¼Æ÷Æó·Å.
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç.
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç.(¡­ðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte activating factor (LAF)
    ¸²ÇÁ±¸ Ȱ¼ºÈ­ÀÎÀÚ
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸À¯·¡ È­ÇÐÁÖ¼ºÀÎÀÚ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁøÀÎÀÚ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁø ÀÎÀÚ
  • lymphocytosis-promoting factor
    ¸²ÇÁ±¸Áõ´ÙÁõÃËÁøÀÎÀÚ
  • lytic factor
    ¿ëÇØÀÎÀÚ(éÁú°ì×í­).
  • macrophage activating factor (MAF)
    ´ë½Ä¼¼Æ÷ Ȱ¼ºÀÎÀÚ
  • macrophage aggregating factor
    ´ë½Ä¼¼Æ÷ °áÁýÀÎÀÚ
  • macrophage arming factor
    ´ë½Ä¼¼Æ÷ ¹«ÀåÀÎÀÚ
  • macrophage chemotactic and activating factor
    ´ë½Ä¼¼Æ÷ ÁÖÈ­ ¹× Ȱ¼º ÀÎÀÚ
  • macrophage chemotactic factor (MCF)
    ´ë½Ä¼¼Æ÷ È­ÇÐÁÖ¼ºÀÎÀÚ
  • macrophage migration inhibition factor(mif)
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ (MIF) (¡­ë´ñËîÁò­ì×í­)
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • three-factor cross
    »ïÀÎÀÚ ±³Â÷ (ß²ì×í­Îßó©)
  • thymic humoral factor
    Èä¼± ü¾×ÀÎÀÚ (ýØàÊô÷äûì×í­)
  • thymidine factor
    ŸÀ̵̹ò ÀÎÀÚ (ì×í­)
  • thyrotropic hormone releasing factor
    °©»ó¼±ÀÚ±Ø(Ë£ßÒàÍí©Ð½) È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • transfer factor
    "ÀüÀÌ(ï®ì¹) ÀÎÀÚ(ì×í­), Àü´ÞÀÎÀÚ(îîÓ¹ì×í­)"
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • translocation factor
    ÀüÀ§ ÀÎÀÚ(ï®êÈì×í­)
  • TR factor
    TR ÀÎÀÚ(ì×í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • two-factor cross
    ÀÌÀÎÀÚ ±³Â÷(ì£ì×í­Îßó©)
  • van't Hoff factor
    ¹ÝÆ® È£ÇÁ ÀÎÀÚ(ì×í­)
  • von Willebrand factor
    Æù ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
  • Willebrand factor
    ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
AHF acute heart failure; American Health Foundation; American Hepatic Foundation; American Hospital Form...
AIF anemia-inducing factor; anti-inflammatory; anti-invasion factor
BCF basophil chemotactic factor; bioconcentration factor; breast cyst fluid
BPF bradykinin-potentiating factor; bronchopulmonary fistula; burst-promoting factor
CCF cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
LMW-BCGF Low-molecular-weight B-cell growth factor
MGF Mast cell growth factor
NKSF Natural Killer cell Stimulatory Factor
NFAT Nuclear Factor of Activated T cell
PD-ECGF Platelet-derived endothelial cell growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • enkephalinergic cell
    ¿£ÄÉÆÈ¸°¼º ¼¼Æ÷
  • eosinophilic cell
    È£»ê±¸
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • epithelioid cell
    »óÇÇ¾ç ¼¼Æ÷, À¯»óÇÇ ¼¼Æ÷
    °áÇÙ µîÀÇ À°¾Æ¼º ¿°Áõ Áúȯ¿¡ À־ À°¾Æ ¼Ó¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ´Â Á¶Á÷±¸ÀÇ È£Äª.
  • ethmoid cell
    »ç°ñ ¹úÁý, »ç°ñ ºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ ¼¼Æ÷
  • excretory cell
    ¹è¼³ ¼¼Æ÷
  • fat cell
    Áö¹æ ¼¼Æ÷
  • fetal liver cell
    ÅÂ¾Æ °£ ¼¼Æ÷
    ÅÂ¾Æ °£ ¼¼Æ÷, Á¶Ç÷ stem ¼¼Æ÷°¡ µé¾î ÀÖ°í, µû¶ó¼­ °¢Á¾ ¸é¿ª ¼¼Æ÷ÀÇ Àü±¸ ¼¼Æ÷¸¦ Æ÷ÇÔÇÑ´Ù. ÃÖ±Ù ¸é¿ªºÎÀüÀÇ Áúȯ, ¿¹¸¦ µé¸é ÁßÁñ º¹ÇÕ ¸é¿ª ºÎÀüÁõ¿¡¼­´Â Á¶Á÷ ÀûÇÕ °ñ¼ö¸¦ ¾òÁö ¸øÇÏ´Â °æ¿ì, 8ÁÖ ÀÌÀüÀÇ ÅÂ¾Æ °£¼¼Æ÷ÀÇ À̽ÄÀÌ ÀÌ·ç¾îÁ® Àå±â°£ÀÇ »ýÁ¸ ¿¹¸¦ º¼ ¼ö ÀÖ´Ù.
  • fibroma-theca cell tumor
    ¼¶À¯Á¾-³­Æ÷¸· ¼¼Æ÷Á¾
    ¼¶À¯¾Æ¼¼Æ÷³ª ³­Æ÷¸· ¼¼Æ÷·Î ±¸¼ºµÈ´Ù. ±¸¼º ¼¼Æ÷°¡ ´ëºÎºÐ ³­Æ÷¸· ¼¼Æ÷ÀÎ ÀÌ Á¾¾çÀº È£¸£¸óÀ» »ý»êÇÒ ¼ö ÀÕ´Ù. ±×·¯³ª ¼ø¼öÇÑ ³­Æ÷¸· ¼¼Æ÷Á¾Àº µå¹°°í ´ëºÎºÐ Á¾¾çÀº ÁÖ·Î ¼¶À¯¸ð¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç È£¸£¸óÀ» »ý»êÇÏÁö ¾Ê´Â´Ù. 90%¿¡¼­ ÇÑÂÊ ³­¼Ò¿¡¼­¸¸ ¹ß»ýÇÑ´Ù. Á¾¾çÀº ȸ¹é»öÀÌ¸ç °íÇüÀÌ°í ±¸ÇüÀÌ¸ç ´Ü´ÜÇÏ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¼¶À¯¸ð¼¼Æ÷¿Í ÄݶóÁ¨ °áü Á¶Á÷À¸·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç ³­Æ÷¸· ¼¼Æ÷°¡ È¥ÀçÇÒ ¼ö ÀÖ´Ù. ȯÀÚ´Â °ñ¹ÝÅë°ú °ñ¹Ý Á¾±« µîÀÇ ºñƯÀÌÀû Áõ»óÀ» È£¼ÒÇϰųª º¹¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ³­Æ÷¸· ¼¼Æ÷Á¾Àº ¾Ç¼ºÀÌ ¾ø´Ù.
  • fibrosing basal cell carcinoma
    ¼¶À¯¼º ±âÀú ¼¼Æ÷ ¾Ï
  • Finkeldey cell
    ÇÉÄ̵¥ÀÌ ¼¼Æ÷
    ¸¶Áø ȯÀÚÀÇ ÀÓÆÄ Á¶Á÷¿¡¼­ º¼ ¼ö ÀÖ´Â °Å´ë ¼¼Æ÷.
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷ ¼¼Æ÷, ³­Æ÷ ¼¼Æ÷
  • foreign body giant cell
    À̹° °Å´ë ¼¼Æ÷, À̹° °Å¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
factor Gm A factor that determines certain of the allotypes of human immunoglobulins; found only on the g chains of IgG (gamma-globulin).
(05 Mar 2000)
factor H Former designation for biotin, vitamin B12 analogue or precursor, a glycoprotein that regulates the activity of complement factor C3b; a deficiency results in the lack of inhibition of the alternative haemolytic pathway leading to continuous activation and consumption of factor C3 (haemolytic uraemic syndrome).
(05 Mar 2000)
factor I <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: fibrinogen.
(15 Nov 1997)
factor II <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: thrombin.
(15 Nov 1997)
factor IIa <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly.
Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion.
(18 Nov 1997)
factor II assay A test used to measure the activity of a blood clotting factor (thrombin). This test may be used to evaluate excessive bleeding. Abnormally low factor II assays may be seen in the following conditions: congenital deficiency of factor II, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
factor II deficiency A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs.
Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases.
(27 Sep 1997)
factor III In the clotting of blood, tissue factor or thromboplastin; it initiates the extrinsic pathway by reacting with factor VII and calcium to form factor VIIa.
See: thromboplastin.
(05 Mar 2000)
factor Inv A factor that determines certain of the allotypes of human immunoglobulins; found on the kappa chains of IgG, IgA, IgM, and Bence Jones protein.
(05 Mar 2000)
factor IV In the clotting of blood, calcium ions.
(05 Mar 2000)
factor ix <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
factor ixa <enzyme> Activated form of factor ix. This activation can take place via the intrinsic pathway by the action of factor xia and calcium, or via the extrinsic pathway by the action of factor viia, thromboplastin, and calcium. Factor ixa serves to activate factor x to xa by cleaving the arginyl-leucine peptide bond in factor x.
Registry number: EC 3.4.21.22
(12 Dec 1998)
factor ix assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
factor ix deficiency A form of haemophilia in males that results from a deficiency of clotting factor IX, transmitted as a X-linked trait.
Symptoms include easy bruising, nosebleeds, bleeding gums and bleeding into muscle tissue (haematoma) or a joint space (haemarthrosis).
Treatment includes the infusion of factor IX concentrates to normalize blood coagulation.
(27 Sep 1997)
factor P A chemical (postulated by T. Lewis), formed in ischemic skeletal or cardiac muscle, held to be responsible for the pain of intermittent claudication and angina pectoris.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á